Filing Details

Accession Number:
0001209191-23-001404
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-04 19:21:17
Reporting Period:
2023-01-02
Accepted Time:
2023-01-04 19:21:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178879 Amicus Therapeutics Inc. FOLD Pharmaceutical Preparations (2834) 200422823
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1755662 Michael David Clark 3675 Market Street
Philadelphia PA 19104
Chief People Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-01-02 11,336 $12.21 198,696 No 4 F Direct
Common Stock Disposition 2023-01-03 8,493 $12.03 190,203 No 4 S Direct
Common Stock Acquisiton 2023-01-03 59,372 $0.00 249,575 No 4 A Direct
Common Stock Disposition 2023-01-03 5,810 $11.93 243,765 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 S Direct
No 4 A Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Acquisiton 2023-01-03 105,388 $0.00 105,388 $11.93
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
105,388 2033-01-03 No 4 A Direct
Footnotes
  1. The sale of common stock was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.82 to $12.24. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 3, 2024 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
  4. These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.